Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.97) per share which missed the analyst consensus estimate of $(0.78) by 24.36 percent. This is a 10.23 percent decrease over losses of $(0.88) per share from the same period last year. The company reported quarterly sales of $2.871 million which missed the analyst consensus estimate of $14.798 million by 80.60 percent. This is a 61.17 percent decrease over sales of $7.394 million the same period last year.